| Title: | Genome-wide association study of asthma with high treatment burden and/or worse outcomes defined using electronic healthcare data in UK Biobank |
| Journal: | ERJ Open Research |
| Published: | 23 Apr 2026 |
| DOI: | https://doi.org/10.1183/23120541.00327-2026 |
Publication 17859
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Background In approximately 10% of asthma patients, symptoms remain uncontrolled despite maximal treatment, representing an unmet clinical need. The causal variants, genes and pathways underlying genetic risk factors have not been fully elucidated, and it is unclear whether there are unique genetic risk factors for this asthma subtype. Methods We used electronic healthcare records (EHR) linked to UK Biobank to identify asthma patients with high treatment burden and/or worse outcomes. We performed a genome-wide association study (GWAS) with this case population and healthy controls. We sought replication for associated (p≤5×10 −6 ) signals in four independent studies (12 152 cases and 32 316 controls). Replicated signals were fine-mapped and linked to genes and pathways. Results In total, 7681 participants met our case definition and showed enrichment for adult-onset asthma, female gender and higher BMI compared to asthma individuals not meeting case criteria. GWAS with 7681 cases and 38 405 controls revealed 21 reproducible association signals that had previously been associated with asthma but had a larger effect size in our study. Variant-to-gene mapping highlighted 85 candidate genes, five of which were considered high confidence ( BACH2 , D2HGDH , IL1RL1 , RPS26 , SMAD3 ). Conclusion We present the first use of EHR in UK Biobank to identify a subtype of asthma enriched for patients with high treatment burden and/or worse outcomes. Our findings support the role of known asthma genes, highlighting genetic risk variants with stronger effect in these groups of patients. The prioritised genes provide potential therapeutic opportunities for this difficult-to-treat patient population. </p>
45 Authors
- Noemi N. Piga
- Michael A. Portelli
- Nick Shrine
- Jing Chen
- Richard Packer
- Kayesha Coley
- Alexander T. Williams
- Chiara Batini
- Catherine John
- Sharon M. Lutz
- Kirsten R. Voorhies
- Albert M. Levin
- Nazanin Zounemat-Kermani
- James E. Gern
- Diane R. Gold
- Tina V. Hartert
- Daniel J. Jackson
- Christine C. Johnson
- Gurjit K. Khurana Hershey
- Rachel L. Miller
- Christine M. Seroogy
- Edward M. Zoratti
- Don D. Sin
- Maarten van den Berge
- Yohan Bossé
- Robert J. Hall
- Dominick Shaw
- Zara E. K. Pogson
- Andrew Fogarty
- Liam G. Heaney
- Adel H. Mansur
- Rekha Chaudhuri
- Neil C. Thomson
- John W. Holloway
- Kian Fan Chung
- John D. Blakey
- Louise V. Wain
- Carole Ober
- Ann C. Wu
- Ian M. Adcock
- Ian P. Hall
- Christopher E. Brightling
- Glenda Lassi
- Ian Sayers
- Katherine A. Fawcett
Enabling scientific discoveries that improve human health